Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da893011a45950c7b74fd8a7174753d8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2013-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90876f7cee9d829a31f75e0b5da1e2b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fe973c038cff0b53b978e9d1d9c459c |
publicationDate |
2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2868907-A1 |
titleOfInvention |
Anti-hla-b*27 antibodies and uses thereof |
abstract |
The present invention provides antibodies and antigen-binding fragments thereof that specifically bind HLA-B*27 (also called HLA-B27). In certain embodiments, the antibodies of the invention bind soluble and/or cell surface-expressed forms of HLA-B*27. The antibodies of the present invention, in certain embodiments, inhibit HLA-B*27-mediated activation of T cells. Certain exemplary antibodies of the present invention exhibit enhanced binding to HLA-B*27 as compared to other HLA-B allelic variants (e.g., HLA-B*07). The present invention also provides anti-HLA-B*27 antibodies with pH-dependent binding characteristics (e.g., higher affinity binding at neutral pH than at acidic pH). The antibodies of the invention are useful for the treatment of diseases and disorders associated with HLA-B*27 expression, including ankylosing spondylitis and other spondyloarthropathies. |
priorityDate |
2012-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |